ODI Pharma AB (XSAT:ODI) Scaled Net Operating Assets: -0.24 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:ODI ODI Pharma AB XSAT:ODI
46 GF Score
Price kr2.54
GF Value kr9.52
Valuation Significantly Undervalued
View Full Analysis

What is ODI Pharma AB Scaled Net Operating Assets?

ODI Pharma AB XSAT:ODI +3.25% 46 Scaled Net Operating Assets is -0.24 as of Mar. 2026. GuruFocus rates XSAT:ODI with a GF Score™ of 46/100 and a GF Value™ of kr9.52 (Significantly Undervalued).

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

ODI Pharma AB's operating assets for the quarter that ended in Mar. 2026 was kr6.34 Mil. ODI Pharma AB's operating liabilities for the quarter that ended in Mar. 2026 was kr8.74 Mil. ODI Pharma AB's Total Assets for the quarter that ended in Dec. 2025 was kr9.93 Mil. Therefore, ODI Pharma AB's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was -0.24.


ODI Pharma AB Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for ODI Pharma AB's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ODI Pharma AB Scaled Net Operating Assets Chart

ODI Pharma AB Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Scaled Net Operating Assets
Get a 7-Day Free Trial 0.08 0.11 -0.37 -0.08 -0.09

ODI Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.18 -0.14 -0.56 -0.38 -0.24

XSAT:ODI vs ZTS, UTHR, VTRS: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ODI Pharma AB's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ODI Pharma AB Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ODI Pharma AB's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where ODI Pharma AB's Scaled Net Operating Assets falls into.


XSAT:ODI
46GF Score
ODI Pharma AB XSAT:ODI
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ODI Pharma AB Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

ODI Pharma AB's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jun. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Jun. 2025 )
=(Operating Assets (A: Jun. 2025 )-Operating Liabilities (A: Jun. 2025 ))/Total Assets (A: Jun. 2024 )
=(3.126-4.186)/12.227
=-0.09

where

Operating Assets(A: Jun. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=4.61 - 1.484
=3.126

Operating Liabilities(A: Jun. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=4.186 - 0 - 0
=4.186

ODI Pharma AB's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(6.34-8.737)/9.934
=-0.24

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=10.527 - 4.187
=6.34

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=8.737 - 0 - 0
=8.737

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -0.24 mean?
ODI Pharma AB (XSAT:ODI) has a Scaled Net Operating Assets of -0.24 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on ODI Pharma AB and its competitors.
Is ODI Pharma AB's Scaled Net Operating Assets too high?
ODI Pharma AB's current Scaled Net Operating Assets is -0.24. Overall, ODI Pharma AB has a GF Score™ of 46/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ODI Pharma AB's Scaled Net Operating Assets compare to ZTS and UTHR?
ODI Pharma AB's Scaled Net Operating Assets of -0.24 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on ODI Pharma AB and its competitors. ODI Pharma AB's current Scaled Net Operating Assets is -0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ODI Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, ODI Pharma AB (XSAT:ODI) is currently considered Significantly Undervalued. The stock's GF Value™ is kr9.52, compared to a current price of kr2.54 — trading 73.3% below its estimated fair value. The current Scaled Net Operating Assets is -0.24. ODI Pharma AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For ODI Pharma AB (XSAT:ODI), the current Scaled Net Operating Assets is -0.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ODI Pharma AB (XSAT:ODI) Overvalued in 2026?

Based on GuruFocus' analysis, ODI Pharma AB stock appears to be undervalued. The current stock price of kr2.54 is trading 73.3% below its estimated GF Value™ of kr9.52. GuruFocus considers ODI Pharma AB to be Significantly Undervalued.

Key valuation signals for XSAT:ODI:

  • Scaled Net Operating Assets: -0.24
  • GF Value™: kr9.52 vs. price of kr2.54 (73.3% below fair value)
  • GF Score™: 46/100

No single metric tells the full story. See the XSAT:ODI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ODI Pharma AB Business Description

Address Ostermalmstorg 1, Stockholm, SWE, 114 42
ODI Pharma AB is a provider of medicinal cannabis. It offers its products to pharmacies, specialty clinics, and hospitals.
46GF Score

Get the complete analysis for XSAT:ODI

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.54
Price
kr9.52
GF Value